MD+DI Online is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
HomeBusinessDiving into Medtech's M&A in 2021
Let’s Talk Medtech

Diving into Medtech's M&A in 2021

Glenn Hunzinger, US Pharma & Life Science Leader for PricewaterhouseCoopers discusses the Pharmaceutical and life sciences deals insights: 2021 midyear outlook report. Hunzinger also talks about some trends in medtech M&A and the rise of the Special Purpose Acquisition Corporation mergers. Plus, MD+DI’s Omar Ford gives insight on Illumina’s controversial acquisition of Grail.

onephoto-stock.adobe.comIMG_Aug262021at30601PM.jpg

This episode of Let’s Talk Medtech is a double-header. We speak with Glenn Hunzinger, US Pharma & Life Science Leader for PricewaterhouseCoopers about the state of medtech M&A and take a dive into the Pharmaceutical and life sciences deals insights: 2021 midyear outlook report.

Then, Omar Ford, MD+DI’s Managing Editor, delves into the controversial Illumina/Grail merger.

 

 

TAGS: Let's Talk Medtech
Hide comments
account-default-image
user not logged in

More information about text formats

Comments

  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Publish
Related
BIOMEDevice_4c.png
BIOMEDevice Boston 2022
revenue growth (2).jpg
Inari Beats Consensus, Announces New CEO
Aug 04, 2022
insomnia (1).jpg
ResMed Strengthens Sleep Portfolio with Mementor Acquisition
Aug 03, 2022
partnership (1).jpg
Collaboration Shows Conformis Still Holds on Tight to Custom Implants
Aug 02, 2022